Rezolute, Inc.
Close on Oct 19, 2026
- Market cap
- $386.60M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Sep 24, 2026 | After market close | – | $-0.20 | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | $-0.16 | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | – | $-0.22 | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q4 FY2025 Ended Jun 30, 2025 | Sep 17, 2025 | After market close | – | – | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | $-0.27 | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 12, 2025 | After market close | – | $-0.22 | – |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 19, 2024 | After market close | – | $-0.44 | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 13, 2024 | After market close | – | $-0.27 | – |
Press releases
Announcements Rezolute filed with the SEC
Rezolute Announces Completion of Enrollment
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces FDA Recommendation to Hold a Pre-BLA
Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rezolute Announces Oral Presentation of Results
Regulation FD disclosure · EX-99.1 to Form 8-K
Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports Second Quarter Fiscal 2026
Results of operations · EX-99.1 to Form 8-K
Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Regulation FD disclosure · EX-99.1 to Form 8-K
Tumor HI EAP Patient Profiles
Regulation FD disclosure · EX-99.2 to Form 8-K
A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation
Regulation FD disclosure · EX-99.3 to Form 8-K
Rezolute Investor Event: Ersodetug Development Program November 10, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter Fiscal 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Regulation FD disclosure · EX-99.1 to Form 8-K
A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation NASDAQ: RZLT
Regulation FD disclosure · EX-99.2 to Form 8-K
Rezolute Appoints Seasoned Commercial Executive
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Baseline demographics and disease characteristics were consistent with published
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports Third Quarter Fiscal 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Rezolute, Inc. Announces Closing of Underwritten
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Announces Pricing of Offering of $90
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rezolute Announces Positive Recommendation After
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports Second Quarter Fiscal 2025
Results of operations · EX-99.1 to Form 8-K
Rezolute Provides Update on its Phase 3 sunRIZE
Regulation FD disclosure · EX-99.1 to Form 8-K
Ersodetug is an investigational drug candidate. The FDA has not
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Receives Breakthrough Therapy Designation
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports First Quarter Fiscal 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Regulation FD disclosure · EX-99.1 to Form 8-K
FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain
Regulation FD disclosure · EX-99.2 to Form 8-K
Topline Results: RZ402 - 201 Phase 2 Study in Patients with Diabetic Macular Edema (DME) May 21, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports Positive Topline Results from
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports Third Quarter Fiscal 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Phase 2 RIZE Study Sub-Analyses to be Presented
Regulation FD disclosure · EX-99.1 to Form 8-K
Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Regulation FD disclosure · EX-99.1 to Form 8-K
Rezolute Reports Second Quarter Fiscal 2024
Results of operations · EX-99.1 to Form 8-K
Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due
Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K